ArticleFuture science OA2017
Biocompatible nickel-prussian blue@silver nanocomposites show potent antibacterial activities.
Article in Future science OA, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metal nanoparticles as a promising therapeutic approach for prostate cancer diagnosis and therapy: a comprehensive review.Medical oncology (Northwood, London, England) · 2025Review
- Nanoscale Prussian Blue and Its Analogues: Design and Applications in Infection Control, Wound Healing and Beyond.Pharmaceutics · 2024Review
- Recent progress toward antiangiogenesis application of nanomedicine in cancer therapy.Future science OA · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSilver nanoparticles have long been used as potent antibacterial agents. However, toxicity concerns of silver nanoparticles have limited their successful clinical applications. Hence, development of silver-based novel biocompatible nanomaterials for antibacterial applications is a challenging task. MATERIALS &
methodsAccordingly, in this work, we synthesized a biocompatible silver-based nanocomposite for antibacterial applications. The nanocompostie was characterized by several analytical techniques. The nanocomposite was further tested for its cytotoxicity in cells, chicken embryo and bacteria. RESULTS &
conclusionHerein, we report a simple and cost-effective method for the synthesis of nickel-prussian blue@silver nanocomposites. The nanocomposite is highly stable and shows biocompatibility observed by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.